Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis

Patricia Marcianes,1 Sofia Negro,1,2 Luis García-García,3 Consuelo Montejo,4 Emilia Barcia,1,2 Ana Fernández-Carballido1,2 1Department of Pharmaceutics, School of Pharmacy, University Complutense of Madrid, Madrid, Spain; 2Institute of Pharmaceutical Technology, Uni...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marcianes P, Negro S, García-García L, Montejo C, Barcia E, Fernández-Carballido A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Polysorbate 80 Labrafil Gatifloxacin Nanoparticles Targeting Blood-Brain Barrier Brain delivery Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/da8a6987a11445bebf783069b7dd4127
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da8a6987a11445bebf783069b7dd4127
record_format	dspace
spelling	oai:doaj.org-article:da8a6987a11445bebf783069b7dd41272021-12-02T00:31:21ZSurface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis1178-2013https://doaj.org/article/da8a6987a11445bebf783069b7dd41272017-03-01T00:00:00Zhttps://www.dovepress.com/surface-modified-gatifloxacin-nanoparticles-with-potential-for-treatin-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Patricia Marcianes,1 Sofia Negro,1,2 Luis García-García,3 Consuelo Montejo,4 Emilia Barcia,1,2 Ana Fernández-Carballido1,2 1Department of Pharmaceutics, School of Pharmacy, University Complutense of Madrid, Madrid, Spain; 2Institute of Pharmaceutical Technology, University Complutense of Madrid, Madrid, Spain; 3Multidisciplinary Institute of Cerebral Cartography, University Complutense of Madrid, Madrid, Spain; 4Department of Pharmaceutical and Health Sciences, School of Pharmacy, University CEU-San Pablo, Spain Abstract: A new nanocarrier is developed for the passage of gatifloxacin through the blood–brain barrier to treat central nervous system tuberculosis. Gatifloxacin nanoparticles were prepared by nanoprecipitation using poly(lactic-co-glycolic acid) (PLGA) 502 and polysorbate 80 or Labrafil as surface modifiers. The evaluation of in vivo blood–brain barrier transport was carried out in male Wistar rats using rhodamine-loaded PLGA nanoparticles prepared with and without the surface modifiers. At 30 and 60 minutes after administration, nanoparticle biodistribution into the brain (hippocampus and cortex), lungs, and liver was studied. The results obtained from the cerebral cortex and hippocampus showed that functionalization of rhodamine nanoparticles significantly increased their passage into the central nervous system. At 60 minutes, rhodamine concentrations decreased in both the lungs and the liver but were still high in the cerebral cortex. To distinguish the effect between the surfactants, gatifloxacin-loaded PLGA nanoparticles were prepared. The best results corresponded to the formulation prepared with polysorbate 80 with regard to encapsulation efficiency (28.2%), particle size (176.5 nm), and ζ-potential (-20.1 mV), thereby resulting in a promising drug delivery system to treat cerebral tuberculosis. Keywords: polysorbate 80, Labrafil, gatifloxacin, nanoparticles, targeting, blood–brain barrier, brain deliveryMarcianes PNegro SGarcía-García LMontejo CBarcia EFernández-Carballido ADove Medical PressarticlePolysorbate 80LabrafilGatifloxacinNanoparticlesTargetingBlood-Brain BarrierBrain deliveryMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 1959-1968 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Polysorbate 80 Labrafil Gatifloxacin Nanoparticles Targeting Blood-Brain Barrier Brain delivery Medicine (General) R5-920
spellingShingle	Polysorbate 80 Labrafil Gatifloxacin Nanoparticles Targeting Blood-Brain Barrier Brain delivery Medicine (General) R5-920 Marcianes P Negro S García-García L Montejo C Barcia E Fernández-Carballido A Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis
description	Patricia Marcianes,1 Sofia Negro,1,2 Luis García-García,3 Consuelo Montejo,4 Emilia Barcia,1,2 Ana Fernández-Carballido1,2 1Department of Pharmaceutics, School of Pharmacy, University Complutense of Madrid, Madrid, Spain; 2Institute of Pharmaceutical Technology, University Complutense of Madrid, Madrid, Spain; 3Multidisciplinary Institute of Cerebral Cartography, University Complutense of Madrid, Madrid, Spain; 4Department of Pharmaceutical and Health Sciences, School of Pharmacy, University CEU-San Pablo, Spain Abstract: A new nanocarrier is developed for the passage of gatifloxacin through the blood–brain barrier to treat central nervous system tuberculosis. Gatifloxacin nanoparticles were prepared by nanoprecipitation using poly(lactic-co-glycolic acid) (PLGA) 502 and polysorbate 80 or Labrafil as surface modifiers. The evaluation of in vivo blood–brain barrier transport was carried out in male Wistar rats using rhodamine-loaded PLGA nanoparticles prepared with and without the surface modifiers. At 30 and 60 minutes after administration, nanoparticle biodistribution into the brain (hippocampus and cortex), lungs, and liver was studied. The results obtained from the cerebral cortex and hippocampus showed that functionalization of rhodamine nanoparticles significantly increased their passage into the central nervous system. At 60 minutes, rhodamine concentrations decreased in both the lungs and the liver but were still high in the cerebral cortex. To distinguish the effect between the surfactants, gatifloxacin-loaded PLGA nanoparticles were prepared. The best results corresponded to the formulation prepared with polysorbate 80 with regard to encapsulation efficiency (28.2%), particle size (176.5 nm), and ζ-potential (-20.1 mV), thereby resulting in a promising drug delivery system to treat cerebral tuberculosis. Keywords: polysorbate 80, Labrafil, gatifloxacin, nanoparticles, targeting, blood–brain barrier, brain delivery
format	article
author	Marcianes P Negro S García-García L Montejo C Barcia E Fernández-Carballido A
author_facet	Marcianes P Negro S García-García L Montejo C Barcia E Fernández-Carballido A
author_sort	Marcianes P
title	Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis
title_short	Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis
title_full	Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis
title_fullStr	Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis
title_full_unstemmed	Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis
title_sort	surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/da8a6987a11445bebf783069b7dd4127
work_keys_str_mv	AT marcianesp surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis AT negros surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis AT garciagarcial surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis AT montejoc surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis AT barciae surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis AT fernandezcarballidoa surfacemodifiedgatifloxacinnanoparticleswithpotentialfortreatingcentralnervoussystemtuberculosis
_version_	1718403710426546176

Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis

Ejemplares similares